Related Experiment Video
Updated: Sep 14, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Survival-inferred fragility of statistical significance in phase III oncology trials
Alexander D Sherry1,2, Yufei Liu3, Pavlos Msaouel4,5
1Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. alexanderdsherry@gmail.com.
Abstract:
In phase III oncology trials, superiority is defined by statistical significance using P thresholds. However, this approach has been criticized because P is continuous. Here, we reconstruct patient-level data for 230 phase III oncology trials to model the robustness of statistical significance by estimating the survival-inferred fragility index (SIFI), defined as the smallest number of patients changing arms that alters the statistical significance interpretation. The median SIFI was 8 patients (IQR 4-19), representing 1.4% of enrollments (IQR 0.7%-3%). As a continuous statistic, P-but not the significance interpretation-was correlated with SIFI. Moreover, overall survival endpoints were more fragile than surrogate endpoints. Taken together, while phase III oncology trials are intended to robustly inform patient care, shifting the assignment of a few patients is often sufficient to upend the statistical significance interpretation. This vulnerability underscores the need for more robust strategies to identify superiority in oncology.
Related Concept Videos
Cancer Survival Analysis
Comparing the Survival Analysis of Two or More Groups
Assumptions of Survival Analysis
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials
There are four phases in a clinical trial. A phase one...

